AMENDMENT - Claims

Please amend the claims, as follows:

1. (currently amended) A method for treating ~~or preventing~~ a disease or disorder in a ~~mammal~~ patient, comprising~~:~~ administering to a patient ~~an agent to the mammal in~~ an effective amount ~~effective to treat or prevent the disease or disorder wherein the~~ of an agent that binds a sphingolipid or a sphingolipid metabolite to reduce the effective concentration thereof, wherein the agent treats a ~~and the~~ disease or disorder ~~is~~ selected from the group consisting of~~:~~ cancer, angiogenesis, and inflammation.

2. (currently amended) The method of claim 1, wherein said agent is an antibody or antibody derivative.

3. (currently amended) The method of claim 1, wherein said agent is a non-catalytic derivative of an enzyme involved in ~~the~~ a sphingolipid metabolic pathway~~s~~.

4. (currently amended) The method of claim 1, wherein said agent is a soluble fragment of a receptor that binds a sphingolipid or a sphingolipid metabolite.

5. (currently amended) The method of claim 1, wherein said sphingolipid or a sphingolipid metabolite is selected from the group consisting of sphingomyelin, sphingosine, sphingolipid-1-phosphate (S-1-P), ceramide, sphingosylphosphorylcholine (SPC), 3-ketosphinganine, galactosylceramide, and dihydroceramide.

6. (currently amended) The method of claim 1, wherein said sphingolipid is selected from the group consisting of ceramide, sphingosine, and sphingolipid-1-phosphate (S-l-P).

7. (currently amended) The method of claim 4, wherein said sphingolipid is sphingolipid-1-phosphate (S-1-P).

8. (currently amended) The method of claim 7, wherein said receptor is selected from the group consisting of Edg-1, Edg-3, Edg-5, Edg-6, Edg-8, ~~the~~ a Mil receptor, AXOR29, NRG1,

SCaMPER, and homologs and isoforms thereof.

9. (originally presented) The method of claim 7, wherein said receptor is an Edg receptor.

10. (originally presented) The method of claim 9, wherein said Edg receptor is rat Edg-3 receptor encoded by a nucleic acid having the sequence SEQ ID NO:7.

11. (currently amended) The method of claim ~~10~~ 7, wherein said receptor is a SCaMPER.

12. (originally presented) The method of claim 11, wherein said SCaMPER is encoded by a nucleic acid selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

13. (currently amended) The method of claim 1, wherein the disease or disorder is cancer.

14. (currently amended) The method of claim 1, wherein the disease or disorder is angiogenesis.

15. (currently amended) The method of claim 1 wherein the disease or disorder is inflammation.

16-25. (canceled)